Ando Y, Jou JH Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis (Hoboken). 2021; 17:(1)23-28

Bacon B, O'Grady J, DiBisceglie A, Lake J, 2nd edition. London: Mosby; 2005

British Society of Gastroenterology. 2009. (accessed 15 August 2022)

British Society of Gastroenterology. 2020. (accessed 15 August 2022)

Brown BG, Crowley J Is there any hope for vitamin E?. JAMA. 2005; 293:(11)1387-1390

Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease. Int J Endocrinol. 2015; 2015:1-9

Chalasani N, Younossi Z, Lavine JE The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55:(6)2005-2023

De Vincentis A, Tavaglione F, Spagnuolo R Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. Int J Obes. 2022; 46:(3)486-493

Ebadi M, Ip S, Bhanji RA, Montano-Loza AJ Effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis: systematic review with meta-analysis of observational studies. Nutrients. 2021; 13:(9)

Ebbeling CB, Knapp A, Johnson A Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia—a randomized controlled feeding trial. Am J Clin Nutr. 2022; 115:(1)154-162

Eslam M, Newsome PN, Sarin SK A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020a; 73:(1)202-209

Eslam M, Sanyal AJ, George J International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020b; 158:(7)

EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64:(6)1388-1402

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020; 5:(3)245-266

Heath RD, Brahmbhatt M, Tahan AC, Ibdah JA, Tahan V Coffee: the magical bean for liver diseases. World J Hepatol. 2017; 9:(15)689-696

Huang J, Kumar R, Wang M, Zhu Y, Lin S MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?. J Hepatol. 2020; 73:(5)1265-1267

Hudson M, Sheron N, Rowe IA, Hirschfield GM Should we screen for cirrhosis?. BMJ. 2017; 358

Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: big wave or ripple?. Clin Mol Hepatol. 2021; 27:(2)257-269

Lazarus JV, Mark HE, Anstee QM NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022; 19:(1)60-78

McPherson S, Armstrong MJ, Cobbold JF Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterol Hepatol. 2022; 7:(8)755-769

McPherson S, Stewart SF, Henderson E, Burt AD, Day CP Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010; 59:(9)1265-1269

Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005; 142:(1)37-46

Mortimore G New year, new lifestyle. Gastrointestinal Nursing. 2021; 19:(Sup10)

Mortimore G, Mayes JP Abdominal ultrasound scans for diagnostic imaging of the liver. Gastrointestinal Nursing. 2019; 17:S30-S35

National Institute of Health and Care Excellence. 2016. (accessed 15 August 2022)

NHS England. 2022. (accessed 15 August 2022)

Oliver TI, Sharma B, John S Portal hypertension.Treasure Island (FL): StatPearls Publishing; 2022

O'Neill BJ Effect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome. Curr Opin Endocrinol Diabetes Obes. 2020; 27:(5)301-307

Pathik P, Ravindra S, Ajay C, Prasad B, Jatin P, Prabha S Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India. Ann Gastroenterol. 2015; 28:(2)281-286

Perumpail B, Li A, John N The role of vitamin E in the treatment of NAFLD. Diseases. 2018; 6:(4)

Portillo-Sanchez P, Bril F, Maximos M High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015; 100:(6)2231-2238

Public Health England. 2020a. (accessed 15 August 2022)

Public Health England. 2020b. (accessed 15 August 2022)

Sterling RK, Lissen E, Clumeck N APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43:(6)1317-1325

Vali Y, Lee J, Boursier J Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2020; 73:(2)252-262

Williams R Liver disease in the UK: startling findings & urgent need for action. J Hepatol. 2015; 63:(2)297-299

Williams R, Alexander G, Armstrong I Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet. 2018; 391:(10125)1097-1107

Wong RJ, Aguilar M, Cheung R Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148:(3)547-555

Younossi ZM, Rinella ME, Sanyal AJ From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology. 2021; 73:(3)1194-1198

Non-alcoholic fatty liver disease: a global concern

02 September 2022
Volume 33 · Issue 9


Non-alcoholic fatty liver disease is an umbrella term used to describe a build-up of fat in the liver. Gerri Mortimore provides an overview of the condition, its diagnosis, treatment and the role of the practice nurse in health promotion

In the early stages of non-alcoholic fatty liver disease (NAFLD), the condition does not cause damage and is reversible. If left untreated, it can develop into the more serious form of non-alcoholic steatohepatitis (NASH), where the liver becomes inflamed, and over time can further develop into fibrosis and cirrhosis. Obesity is associated with the development of NAFLD. Any patient who falls in the obese category and/or has type 2 diabetes or insulin resistance and/or is diagnosed with metabolic syndrome should be tested for NAFLD. Nurses are often in the best position to prompt early investigation. Health promotion in the form of lifestyle advice is the mainstay of treatment, with an emphasis on weight reduction and healthy diet.

Liver disease is a global issue and is recognised as the fifth leading cause of death worldwide (Global Burden of Disease, 2020). Over the last 50 years, the UK has witnessed an exponential increase in liver disease mortality whereas death rates from other medical conditions such as cancer, heart and respiratory disease have fallen (British Society of Gastroenterology (BSG), 2009; Williams, 2015; Williams et al, 2018; British Liver Trust (BLT), 2019; Public Health England (PHE), 2020a).

Liver disease is the third most common cause of premature death in those under 65 years old (BSG, 2009; PHE, 2017; BLT, 2019; PHE, 2020a), with death rates in this cohort group increasing by over 400% since the 1970s (BLT, 2019), and is the second leading cause of death for people aged 35–49 years, accounting for 9.8% of deaths in that age group (, 2022). These findings are supported by data published in 2015 by PHE which additionally report that over 600 000 people in the UK have some form of serious liver disease with over 60 000 diagnosed with liver cirrhosis. Further statistics published in the Lancet Standing Commission on Liver Disease in the UK report (Williams et al, 2018), emphasised this stark reality and postulated that liver disease could overtake ischaemic heart disease with regards to years of working life lost. This fact was confirmed in England in 2020 by the government reporting that working lives lost by liver disease overtook ischaemic heart disease and accidental poisoning (, 2022).

Register now to continue reading

Thank you for visiting Practice Nursing and reading some of our peer-reviewed resources for general practice nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month